|58.10||-0.7100||-1.21%||Vol 2.29M||1Y Perf -12.76%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||-0.01 -0.02%|
|Target Price||82.45||Analyst Rating||Moderate Buy 2.07|
|Potential %||41.91||Finscreener Ranking||★★★+ 51.51|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 56.36|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 70.21|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||-1.59||Earnings Rating||Strong Buy|
|Market Cap||13.02B||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||7th Nov 2023|
|Estimated EPS Next Report||0.91|
|EPS Growth Next 5 Years %||7.00|
|Avg. Weekly Volume||2.50M|
|Avg. Monthly Volume||1.71M|
|Avg. Quarterly Volume||1.57M|
Incyte Corporation (NASDAQ: INCY) stock closed at 58.1 per share at the end of the most recent trading day (a -1.21% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 13.02B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.
The one-year performance of Incyte Corporation stock is -12.76%, while year-to-date (YTD) performance is -27.66%. INCY stock has a five-year performance of -12.75%. Its 52-week range is between 58.54 and 86.29, which gives INCY stock a 52-week price range ratio of -1.59%
Incyte Corporation currently has a PE ratio of 20.60, a price-to-book (PB) ratio of 4.26, a price-to-sale (PS) ratio of 7.11, a price to cashflow ratio of 22.50, a PEG ratio of 2.94, a ROA of 19.32%, a ROC of 23.53% and a ROE of 25.41%. The company’s profit margin is 12.65%, its EBITDA margin is 19.10%, and its revenue ttm is $2.47 Billion , which makes it $11.09 revenue per share.
Of the last four earnings reports from Incyte Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.91 for the next earnings report. Incyte Corporation’s next earnings report date is 07th Nov 2023.
The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2.07), with a target price of $82.45, which is +41.91% compared to the current price. The earnings rating for Incyte Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Incyte Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 12.13, ATR14 : 1.34, CCI20 : -179.28, Chaikin Money Flow : -0.14, MACD : -1.28, Money Flow Index : 32.83, ROC : -8.06, RSI : 28.05, STOCH (14,3) : 2.62, STOCH RSI : 0.00, UO : 28.96, Williams %R : -97.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Dashyant Dhanak (Option Excercise at a value of $241 596), Dashyant Dhanak (Sold 2 419 shares of value $205 615 ), Dhanak Dashyant (Option Excercise at a value of $241 596), Dhanak Dashyant (Sold 2 419 shares of value $205 615 ), Maria E. Pasquale (Option Excercise at a value of $4 405 224), Maria E. Pasquale (Sold 60 024 shares of value $5 086 567 ), Pasquale Maria (Option Excercise at a value of $4 465 197), Pasquale Maria (Sold 60 826 shares of value $5 153 983 ), Stein Steven (Sold 49 910 shares of value $3 626 888 ), Steven H. Stein (Sold 28 399 shares of value $2 265 672 ), Swain Paula (Sold 8 449 shares of value $550 283 ), Thomas Tray (Sold 1 223 shares of value $100 482 ), Vijay Iyengar (Option Excercise at a value of $480 340), Vijay Iyengar (Sold 7 000 shares of value $595 000 ), Vijay K. Iyengar (Option Excercise at a value of $1 533 797), Vijay K. Iyengar (Sold 24 324 shares of value $1 994 739 )
Wed, 02 Aug 2023 11:15 GMT Incyte (INCY) Gets a Hold from BMO Capital- TipRanks. All rights reserved.
Tue, 25 Jul 2023 11:10 GMT Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Alnylam Pharma (ALNY)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.